Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CUPID: Phase I Study of 64Cu-TLX592 in Prostate Cancer
NCT04726033Phase 1Completed
- Sponsor
- Telix Pharmaceuticals Limited
- Start
- Aug 2021
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of TLX592 in Metastatic Prostate Cancer (mPC) (4 arms), sponsored by Telix Pharmaceuticals Limited. Primary endpoints: Treatment-Related Adverse Events, Pharmacokinetics of 64Cu-TLX592 at Day 4 and 2 more. Started Aug 2021; status: completed.
02
Drugs
TLX592
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT04726033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04726033.